AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of AK104 plus concurrent
chemoradiation therapy in unresectable locally advanced esophageal squamous cell carcinoma
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of University of South China